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  ABSTRACT 
  This ﬁ  rst up  date of the ASAS/EULAR recommendations 
on the management of anky  lo  sing spondylitis (AS) is 
based on the original paper, a systematic review of 
existing recommendations and the literature since 2005 
and the discussion and agreement among 21 international 
experts, 2 patients and 2 physiotherapists in a meeting in 
February 2010. Each original bullet point was discussed 
in de  tail and rewor  ded if necessary. Decisions on new 
re  com  men    da  tions were made — if necessary after 
voting. The strength of the recommen    dations (SOR) 
was scored on an 11-point nume  rical rating scale after 
the meeting by email. These recommendations apply to 
patients of all ages that fulﬁ  ll the modiﬁ  ed NY criteria for 
AS, independent of extra-ar  ticu  lar manifestations, and 
they take into ac  count all drug and non-drug interventions 
related to AS. Four overarching principles were intro-
duced, implying that one bullet has been moved to this 
section. There are now 11 bullet points in  clu  ding 2 new 
ones, one related to extra-articular manife  sta  tions and 
one to changes in the disease course. With a mean score 
of 9.1 (range 8-10) the SOR was generally very good.              
  The European League against Rheumatism 
(EULAR) has developed management recom-
mendations for various rheumatic conditions in 
the past decade    1       –       6    based on standard operating 
procedures published some years ago.    7    The basis 
for the methodology is the AGREE instrument.    8    
A systematic literature review (SLR) serves as the 
basis for the expert discussions and the consen-
sus process.    9       –       11    The Assessments in Ankylosing 
Spondylitis International Society (ASAS), which 
published a core set of endpoints for the disease 
more than 10 years ago    12    has taken the lead in 
developing recommendations for anti-tumour 
necrosis factor (TNF) therapy in ankylosing spon-
dylitis (AS),    13    which have already been updated 
twice.    14        15    The two organisations jointly devel-
oped the ﬁ   rst set of recommendations for the 
management of AS together in 2005. 
  As this is a requirement of the EULAR standard 
operating procedures for management recommen-
dations and as the ﬁ  eld of spondyloarthritis is mov-
ing rapidly, an update of the ﬁ  rst recommendations 
for the management of AS is needed after 5 years. 
  While the ﬁ  rst version of the management rec-
ommendations was initially developed without 
patients, and as discrepancies between patients’ 
  For numbered afﬁ  liations see 
end of article.
  Correspondence to 
  Professor Dr J Braun, 
Rheumazentrum Ruhrgebiet, 
Landgrafenstrasse 15, 44652 
Herne, Germany; 
 j.braun@rheumazentrum-
ruhrgebiet.de                                        
and physicians’ perspectives are well known,    16    on 
this occasion patients were involved in the project 
group from the beginning. Moreover, other stake-
holders, such as physiotherapists, were also rep-
resented in the project group. A patient-speciﬁ  c 
version of the ﬁ   rst recommendations has been 
developed with the active support of patients of 
many European and North American countries.    17    
The original and the patient version of the recom-
mendations has been evaluated    18        19    and dissemi-
nated in several countries.    20       –       23    
  AS is the prototype,    24    a subtype, and an out-
come of spondyloarthritis, particularly of the axial 
form of spondyloarthritis. Recent new classiﬁ  ca-
tion criteria have widened the spectrum of spon-
dyloarthritis by including earlier forms in addition 
to AS.    25        26    This project has also led to a separa-
tion in the classiﬁ   cation to predominantly axial 
and peripheral forms of spondyloarthritis. The 
term ‘axial spondyloarthritis’ covers patients with 
chronic back pain who have AS, which is deﬁ  ned 
by the presence of deﬁ  nite structural changes on 
radiographs in the sacroiliac joints, and patients 
with early or abortive forms of spondyloarthri-
tis, which is deﬁ  ned by the presence of sacroiliac 
inﬂ  ammation as detected by MRI or the presence 
of HLA B27 in combination with the presence of 
features typical of spondyloarthritis.    27        28    It can be 
anticipated that future trials will increasingly target 
axial spondyloarthritis rather than AS. Some trials 
with that aim have already been performed and 
some have started. However, as the evidence from 
such trials is currently limited it has been decided 
to restrict the recommendations to AS, although 
the project group unanimously agreed that these 
recommendations can equally be applied to 
patients with axial spondyloarthritis. 
  As the number of clinical trials and publications 
on AS therapy has steadily increased over the ﬁ  rst 
decade of the millennium, this provided a sound 
rationale for a SLR. 
  METHODS 
  ASAS and EULAR agreed in 2009 to collaborate 
in the development of the ﬁ  rst update of the rec-
ommendations. To facilitate the process, it was 
decided that the convenor (JB) and the epidemi-
ologist (DvdH) would maintain the same role that 
they undertook in the development of the ﬁ  rst 
recommendations. 
        2010  update  of  the  ASAS/EULAR  recommendations 
for the management of ankylosing spondylitis   
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  These original recommendations    1    formed the basis for the 
update. Two fellows performed the SLR, which needed an 
update since 2005 when the previous SLR was performed.    11    
The international expert group included 21 rheumatologists, 
two orthopaedic surgeons, four patients (two of them were 
also rheumatologists) and one physiotherapist—representing 
16 countries worldwide. The same group of international AS 
experts who participated in the development of the ﬁ  rst recom-
mendations was invited to participate. 
  The experts met on 15/26 February 2010 in Zurich. During 
the meeting, the data from the SLR dating from the previous 
search in 2005 until December 2009 were presented to the inter-
national experts. Each bullet point was discussed in detail until 
consensus was reached as to whether rewording was necessary. 
New recommendations were considered if this was proposed 
by a member of the panel. 
  Scoring on an 11-point numerical rating scale for the strength 
of recommendation was done by email by each expert for each 
bullet point after the meeting. 
  The methodology and detailed results of the SLR are 
described elsewhere in two separate papers: one dealing with 
biological agents and the other with all other management 
aspects such as non-biological drugs, education and physio-
therapy (submitted).   
  RESULTS 
  General  deﬁ  nitions 
  The target population was deﬁ  ned as follows: the recommenda-
tions were to apply to all patients fulﬁ  lling the modiﬁ  ed New 
York criteria for AS, independent of extra-articular manifesta-
tions. Patients of all ages, including paediatric patients, were 
included, and all pharmacological and non-pharmacological 
interventions for AS were taken into account. 
  The ﬁ  rst discussion addressed whether the terminology of 
the recommendations should be changed to ‘Recommendations 
for the management of axial spondyloarthritis’. The arguments 
in favour were mainly that the new classiﬁ  cation criteria for 
axial spondyloarthritis    25        26    are now available and they should 
therefore be included in the recommendations. The arguments 
against this were rather pragmatic, such as ‘the world of rheu-
matology is not yet ready for that change’. Furthermore, there is 
a paucity of papers in early disease. The group ﬁ  nally decided to 
stick to the term ‘AS’ for the time being. However, every expert 
expressed the opinion that patients with early axial spondyloar-
thritis who do not yet fulﬁ  l the modiﬁ  ed New York criteria are 
part of the same spectrum of disease and that these management 
recommendations most likely apply equally to those patients. 
Importantly, this patient population is already well recognised 
in the last update of the ASAS recommendations for anti-TNF 
therapy.    15    However, it should also be clearly stated that not all 
patients who fulﬁ  l classiﬁ  cation criteria for axial spondyloarthri-
tis will necessarily develop structural damage with radiographic 
changes in the sacroiliac joints and/or spine, which is presently 
considered essential in order for patients to fulﬁ  l currently used 
criteria for AS.    29        30    This is actually similar to patients fulﬁ  lling 
the 2010 criteria for rheumatoid arthritis (RA) versus patients 
fulﬁ  lling the 1987 criteria for RA. 
  Although there are ﬁ  rst hints that TNF blockers may be safer 
in AS compared with RA,    31    a decision was made not to create 
a unique update on the safety of biological agents in AS/spon-
dyloarthritis, but rather to rely on the extensive work done by 
Furst   et al      32    who have undertaken an annual consensus docu-
ment on this topic from the ‘Targeted therapies’ meeting.   
    Results of the SLR 
  The detailed results will be published elsewhere (submitted). 
However, the information that was obtained from the SLR was 
taken into account during the discussions of each bullet point.   
    Results of the discussions 
  The ﬁ  rst change the expert group agreed on was, by analogy 
with other EULAR recommendations (eg, management rec-
ommendations for RA, 6), to deﬁ  ne overarching principles of 
management. 
  Bullet point number 3 in the ﬁ  rst published version of the rec-
ommendations    1    stating that the optimal management of patients 
with AS requires a combination of non-pharmacological and 
pharmacological treatment modalities has now been moved to 
this section. 
  Of note, the citations in this section are not the complete 
results of the SLR and they are not complete. They are just 
examples given to document the basis of the statements and 
notations made in the text. 
  An overview of the new recommendation is given in   box 1  .   
  The overarching principles of the management of patients with 
AS are: 
▶       AS is a potentially severe disease with diverse manifestations, 
usually requiring multidisciplinary treatment coordinated by 
the rheumatologist. 
▶       The primary goal of treating the patient with AS is to maxi-
mise long term health-related quality of life through control 
of symptoms and inﬂ  ammation, prevention of progressive 
structural damage, preservation/normalisation of function 
and social participation. 
▶       Treatment of AS should aim at optimal care and must be 
based on a shared decision between the patient and the 
rheumatologist. 
▶       The optimal management of patients with AS requires a 
combination of non-pharmacological and pharmacological 
treatment modalities. 
    Comment 
  Patients with AS present with different disease manifestations    24    
and a high proportion may run a severe course of disease.    33    The 
main health problems of patients with AS have recently been 
listed as part of an International Classiﬁ  cation of Functioning, 
Disability and Health consensus process.    34        35    
  It is important to stress that the rheumatologist is the expert 
who should take the lead in the management of patients with 
AS. The major aim for the treatment of rheumatic diseases is 
the preservation and gain of short and long-term health-related 
quality of life. The general view is that this is best achieved 
through control of symptoms and inﬂ  ammation—with the aim 
to prevent deformity and disability due to structural damage 
caused by new bone formation and the decline of function and 
social participation. 
  Strength of recommendation: 9.5±0.1. 
  Thereafter, the bullet points were discussed point by point 
in considerable detail, and agreement was achieved on 11 
points. 
  The updated recommendations are: 
    General  treatment 
  The treatment of patients with AS should be individualised 
according to: 
▶       The current manifestations of the disease (axial, peripheral, 
entheseal, extra-articular symptoms and signs) 
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Box 1  First update of the ASAS/EULAR recommendations for the management of AS 
        The overarching principles of the management of patients with AS are: 
▶          AS is a potentially severe disease with diverse manifestations, usually requiring multidisciplinary treatment coordinated by the rheumatologist. 
▶          The primary goal of treating the patient with AS is to maximise long term health-related quality of life through control of symptoms and 
inﬂ  ammation, prevention of progressive structural damage, preservation/normalisation of function and social participation. 
▶        Treatment of AS should aim at the best care and must be based on a shared decision between the patient and the rheumatologist. 
▶          The optimal management of patients with AS requires a combination of non-pharmacological and pharmacological treatment modalities. 
    1.  General  treatment  
      The treatment of patients with AS should be tailored according to: 
▶        The current manifestations of the disease (axial, peripheral, entheseal, extra-articular symptoms and signs). 
▶        The level of current symptoms, clinical ﬁ  ndings, and prognostic indicators. 
▶        The general clinical status (age, gender, comorbidity, concomitant medications, psychosocial factors). 
    2.  Disease  monitoring  
      The disease monitoring of patients with AS should include: 
▶     Patient  history  (eg,  questionnaires) 
▶     Clinical  parameters 
▶     Laboratory  tests 
▶     Imaging 
▷           All according to the clinical presentation as well as the ASAS core set 
          The frequency of monitoring should be decided on an individual basis depending on: 
▶     Course  of  symptoms 
▶     Severity 
▶     Treatment 
    3.  Non-pharmacological  treatment  
▶        The cornerstone of non-pharmacological treatment of patients with AS is patient education and regular exercise. 
▶          Home exercises are effective. Physical therapy with supervised exercises, land or water based, individually or in a group, should be preferred as 
these are more effective than home exercises. 
▶        Patient associations and self-help groups may be useful. 
    4.  Extra-articular  manifestations  and  comorbidities  
▶          The frequently observed extra-articular manifestations, for example, psoriasis, uveitis and IBD, should be managed in collaboration with the 
respective specialists. 
▶          Rheumatologists should be aware of the increased risk of cardiovascular disease and osteoporosis. 
    5.  Non-steroidal  anti-inﬂ  ammatory drugs   
▶        NSAID, including Coxibs, are recommended as ﬁ  rst-line drug treatment for AS patients with pain and stiffness. 
▶        Continuous treatment with NSAID is preferred for patients with persistently active, symptomatic disease. 
▶        Cardiovascular, gastrointestinal and renal risks should be taken into account when prescribing NSAID. 
    6.  Analgesics  
▶          Analgesics, such as paracetamol and opioid (like) drugs, might be considered for residual pain after previously recommended treatments have 
failed, are contraindicated, and/or poorly tolerated. 
    7.  Glucocorticoids  
▶          Corticosteroid injections directed to the local site of musculoskeletal inﬂ  ammation may be considered. 
▶        The use of systemic glucocorticoids for axial disease is not supported by evidence. 
    8.  Disease-modifying  antirheumatic  drugs  
▶        There is no evidence for the efﬁ  cacy of DMARD, including sulfasalazine and methotrexate, for the treatment of axial disease. 
▶        Sulfasalazine may be considered in patients with peripheral arthritis. 
    9.  Anti-TNF  therapy  
▶          Anti-TNF therapy should be given to patients with persistently high disease activity despite conventional treatments according to the ASAS 
recommendations. 
▶          There is no evidence to support the obligatory use of DMARD before or concomitant with anti-TNF therapy in patients with axial disease. 
▶          There is no evidence to support a difference in efﬁ  cacy of the various TNF inhibitors on the axial and articular/entheseal disease manifestations; but 
in the presence of IBD a difference in gastrointestinal efﬁ  cacy needs to be taken into account. 
▶        Switching to a second TNF blocker might be beneﬁ  cial especially in patients with loss of response. 
▶        There is no evidence to support the use of biological agents other than TNF inhibitors in AS. 
    10.  Surgery  
▶          Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent 
of age. 
▶        Spinal corrective osteotomy may be considered in patients with severe disabling deformity. 
▶        In patients with AS and an acute vertebral fracture a spinal surgeon should be consulted. 
        11. Changes in the disease course   
▶         If a signiﬁ  cant change in the course of the disease occurs, other causes than inﬂ  ammation, such as a spinal fracture, should be considered and 
appropriate evaluation, including imaging, should be performed.     
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▶       The level of current symptoms, clinical ﬁ  ndings and prognos-
tic indicators 
▶       The general clinical status (age, gender, comorbidities, con-
comitant medications, psychosocial factors). 
    Comment 
  This general bullet point was not changed. It stresses that there 
may be considerable variation in how AS patients may present 
to the rheumatologist. The aim of management and appropri-
ate interventions may thus also differ substantially. This implies 
that these aims must be tailored to the unique features of the 
particular AS patient. 
  Strength of recommendation: 9.5±0.1. 
    Disease  monitoring 
  The disease monitoring of patients with AS should include: 
▶       Patient history (eg, questionnaires) 
▶       Clinical parameters 
▶       Laboratory tests 
▶       Imaging 
▷           All according to the clinical presentation as well as the 
ASAS core set. 
      The frequency of monitoring should be decided on an indi-
vidual basis depending on: 
▶       Course of symptoms 
▶       Severity 
▶       Treatment. 
    Comment 
  This bullet point was not changed. It basically leaves the deci-
sion as to how frequently patients should be monitored to the 
rheumatologist in charge of management. This is mainly due 
to the fact that the course of disease may differ substantially 
between patients and different aspects, as stated in the bullet 
point, may need to be considered. 
  Importantly, experts agreed that, in general, spinal x-rays 
should not be repeated more frequently than every 2 years 
unless clearly indicated in individual cases. This recommenda-
tion is based on the experience from clinical studies.    36        37    
  Strength of recommendation: 9.4±0.2. 
    Non-pharmacological  treatment 
▶       The cornerstone of non-pharmacological treatment of 
patients with AS is patient education and regular exercise. 
▶       Home exercises are effective. Physical therapy with super-
vised exercises, land or water based, individually or in a 
group, should be preferred as these are more effective than 
home exercises. 
▶       Patient associations and self-help groups may be useful. 
      For comparison, the old recommendation was: non-pharmaco-
logical treatment of AS should include patient education and 
regular exercise. Individual and group physical therapy should 
be considered. Patient associations and self-help groups may be 
useful. 
  Comment 
  This bullet point was changed according to the SLR and the 
recent Cochrane review on the subject,    38    and was supported by 
the view of an experienced physiotherapist (HD) and the par-
ticipating patients. 
  Strength of recommendation: 8.8±0.4. 
    Extra-articular  manifestations  and  comorbidities 
▶       The frequently observed extra-articular manifestations, eg, 
psoriasis, uveitis, and chronic inﬂ  ammatory bowel disease 
(IBD), should be managed in collaboration with the respec-
tive specialists. 
▶       Rheumatologists should be aware of an increased risk of car-
diovascular disease and osteoporosis. 
    Comment 
  This is a new bullet point, with agreement being achieved after 
considerable discussion. The main argument was that extra-
articular manifestations are rather frequent in AS and the entire 
spectrum of spondyloarthritis,    39    and that they constitute a fre-
quent challenge in management that clearly requires coopera-
tion between specialities. 
  On the other hand, there are frequent comorbidities that 
require the attention of the managing rheumatologist. These 
include low bone mineral density, osteoporotic fractures    40        41    and 
cardiovascular diseases,    42        43    which have been reported to occur 
in AS and spondyloarthritis at an increased rate compared with 
the general population. 
  The rheumatologist is encouraged to identify patients at risk 
and the potential additional risk factors. At this time, it is dif-
ﬁ  cult to make a clear-cut recommendation on the management 
of osteopaenia and osteoporosis for patients with AS in the 
absence of any studies on the subject. 
  Regarding the management of cardiovascular risk there are 
recent EULAR recommendations that propose an annual risk 
assessment related to national guidelines.    44    Although this is 
mainly intended for patients with RA, these same guidelines 
should also be considered for patients with AS and psoriatic 
arthritis. Rheumatologists are referred to local guidelines for the 
management of cardiovascular risk and, if no local guidelines are 
available, the management should be carried out according to 
the systematic coronary risk evaluation (SCORE) function    45    (for 
overview see Cooney   et al  ).    46    In addition to appropriate cardio-
vascular risk management, aggressive suppression of the inﬂ  am-
matory process is recommended to lower the cardiovascular risk 
further. 
  Strength of recommendation: 9.0±0.3. 
    Non-steroidal  anti-inﬂ  ammatory drugs 
▶       Non-steroidal anti-inﬂ   ammatory drugs (NSAID), including 
Coxibs, are recommended as ﬁ  rst-line drug treatment for AS 
patients with pain and stiffness. 
▶       Continuous treatment with NSAID is preferred for patients 
with persistently active, symptomatic disease. 
▶       Cardiovascular, gastrointestinal and renal risks should be 
taken into account when prescribing NSAID. 
      For comparison, the old recommendation was: NSAID are recom-
mended as ﬁ  rst-line drug treatment for patients with AS with pain 
and stiffness. In those with increased gastrointestinal risk, non-se-
lective NSAID plus a gastroprotective agent, or a selective COX-2 
inhibitor with or without a gastroprotective agent could be used. 
  Comment 
  This bullet point was subject to some minor modiﬁ  cations but 
the signiﬁ  cance of the statement remains unchanged. 
  The main issues are still that NSAID are recommended as 
the ﬁ  rst-line drug therapy, that NSAID are recommended to 
be taken continuously in active patients, and that NSAID are 
considered relatively safe in the population of patients with AS, 
although the cardiovascular, gastrointestinal and renal risks may 
be somewhat increased in this population. 
  The main challenges are that it is unclear whether a cut-off 
such as a Bath ankylosing spondylitis disease activity index 
of 4 is valuable in classifying patients as responders or non-
  responders with regard to NSAID therapy, whether NSAID 
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should be taken continuously regardless of symptoms by all 
(even asymptomatic) patients to prevent new bone formation, 
whether long-term NSAID therapy is safe, whether patients at 
risk can be readily identiﬁ  ed, and how this should be done in 
clinical practice. 
  There is evidence that NSAID are efﬁ  cacious for the relief 
of pain and stiffness in patients with AS    47    for both short-term 
and prolonged periods of treatment.    48        49    The efﬁ  cacy is, at least 
partly, dose related.    48    There seems to be no effect on spinal 
inﬂ  ammation as assessed by MRI in one small study,    50    but con-
tinuous therapy may be superior in the prevention of new bone 
formation.    51    Coxibs may be safe for short-term therapy even in 
patients with IBD.    52    One recent step forward for clinical trials in 
AS has been the ASAS proposal on how information on NSAID 
intake should be collected in studies.    53    
  Strength of recommendation: 9.3±0.3. 
    Analgesics 
▶       Analgesics, such as paracetamol and opioid-(like) drugs, 
might be considered for residual pain after previously recom-
mended treatments have failed, are contraindicated, and/or 
poorly tolerated. 
    Comment 
  This bullet point has remained unchanged. This topic has been 
the source of frequent discussion and there are experts who have 
proposed eliminating this bullet point, but the majority still felt 
that inclusion of this bullet point was necessary because it was 
important to draw attention to the possibility that not all back 
pain in AS may derive from spinal inﬂ  ammation. 
  Strength of recommendation: 8.0±0.5. 
    Glucocorticoids 
▶       Glucocorticoid injections directed to the local site of muscu-
loskeletal inﬂ  ammation may be considered. 
▶       The use of systemic glucocorticoids for axial disease is not 
supported by evidence. 
    Comment 
  This bullet point has remained unchanged. There have been no 
new studies and the available literature is still scarce. 
  Strength of recommendation: 8.9±0.4. 
    Disease  modifying  antirheumatic  drugs 
▶       There is no evidence for the efﬁ  cacy of disease-modifying 
antirheumatic drugs (DMARD), including sulfasalazine and 
methotrexate, for the treatment of axial disease. 
▶       Sulfasalazine may be considered in patients with peripheral 
arthritis. 
    Comment 
  This bullet point has remained unchanged. After the 
last Cochrane review    54    there were two new studies on 
sulfasalazine,    55        56    but the experts did not ﬁ  nd that these pro-
vided sufﬁ  cient new information to change this bullet point. 
The results of the ﬁ  rst study, which was performed mainly 
in patients who had early spondyloarthritis, are conﬂ  icting,    55    
whereas in the head-to-head trial against etanercept there was 
no placebo group.    56    Overall, a marginal positive effect of sul-
fasalazine with a rather limited effect size in AS cannot be 
excluded. Therefore, no strong recommendation can be given 
to support its use but the rheumatologist may decide on a trial 
of sulfasalazine for a limited period, usually not more than 4 
months, after which further beneﬁ  t is unlikely. The majority 
of the studies suggest some efﬁ  cacy of sulfasalazine in patients 
with peripheral spondyloarthritis and in the prevention of ante-
rior uveitis. However, etanercept was more efﬁ  cacious in the 
active comparator trial.    56    Finally, there is clearly no reason other 
than economic to recommend the obligatory use of a conven-
tional DMARD in AS before anti-TNF therapy. 
  The data on methotrexate are still very limited and no posi-
tive recommendation can be given on an evidence basis. After 
the last Cochrane review    57    there was one new open-label study 
with a high dose of methotrexate given subcutaneously,    58    
which again demonstrated no effect on patients with axial 
disease. 
  Most rheumatologists will try methotrexate in patients with 
predominant peripheral spondyloarthritis, but no evidence-
based recommendation can presently support this. 
  Strength of recommendation: 9.4±0.2. 
    Anti-TNF  therapy 
▶       Anti-TNF therapy should be given to patients with persis-
tently high disease activity despite conventional treatments 
according to the ASAS recommendations. 
▶       There is no evidence to support the obligatory use of 
DMARD before or concomitant with anti-TNF therapy in 
patients with axial disease. 
▶       There is no evidence to support a difference in efﬁ  cacy of the 
various TNF inhibitors on the axial and articular/entheseal 
disease manifestations; but in the presence of IBD a difference 
in gastrointestinal efﬁ  cacy needs to be taken into account. 
▶       Switching to a second TNF blocker might be beneﬁ  cial espe-
cially in patients with loss of response. 
▶       There is no evidence to support the use of biological agents 
other than TNF inhibitors in AS. 
      For comparison, the old recommendation was: anti-TNF treat-
ment should be given to patients with persistently high disease 
activity despite conventional treatments according to the ASAS 
recommendations. There is no evidence to support the obliga-
tory use of DMARD before, or concomitant with, anti-TNF 
treatment in patients with axial disease. 
  Comment 
  This recommendation was substantially changed—based on 
extensive discussions related to the literature review, as the 
vast majority of new studies published in the past 5 years were 
related to anti-TNF therapy. The statement is of course strongly 
related to the recent update of the ASAS recommendations on 
anti-TNF therapy in AS.    15    
  Since the last systematic review    11    there were many new 
studies. In addition to inﬂ  iximab and etanercept, adalimumab    59    
and golimumab    60    have also been approved. There are substan-
tial data on patient-reported outcomes.    61    There is evidence 
that patients with advanced disease    62    also have some beneﬁ  t, 
but patients with early    63    and very early    64    disease seem to have 
even more beneﬁ  t. The highest remission rate reported is up 
to 50% after 16 weeks    64    in patients with inﬂ  ammatory back 
pain    65    of less than 3 years (mean 15 months) and sacroiliitis 
on MRI but not on radiographs. Of note, the majority of the 
patients in these trials did not fulﬁ  l the modiﬁ  ed New York 
criteria for AS. 
  The retention rate of patients with AS after 1 year of anti-TNF 
therapy was better than for patients with RA in a large regis-
try.    66    There is evidence that the efﬁ  cacy of anti-TNF therapy 
lasts over several years.    67       –       69    
  Spinal inﬂ  ammation, as assessed by MRI, improves substan-
tially after anti-TNF therapy.    70    Radiographic progression (mainly 
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new bone formation) does not seem to be inhibited by anti-TNF 
therapy,    71    but there is also no evidence that syndesmophyte for-
mation is accelerated. 
  The major new aspect of the updated recommendations 
is the differential effect of anti-TNF therapy when available 
drugs have similar efﬁ  cacy on musculoskeletal manifestations 
but differential efﬁ  cacy in clinically symptomatic IBD.    72    Here 
the monoclonal antibodies work better than the fusion pro-
tein (inﬂ  iximab is approved for both Crohn’s disease (CD) and 
ulcerative colitis, adalimumab for CD, no data yet available for 
golimumab). The differences regarding acute anterior uveitis 
are less evident.    73    The presence or absence of psoriasis does not 
seem to make a difference as regards efﬁ  cacy on musculoskel-
etal symptoms.    74    
  There is evidence that anti-TNF agents improve the signs and 
symptoms of peripheral arthritis and enthesitis.    75        76    
  Furthermore, a recommendation for switching is included for 
the ﬁ  rst time since several studies have suggested high success 
rates.    77       –       79    It was discussed that antibody formation    80        81    may be 
involved in the phenomenon of loss of response (secondary non-
response) and that such patients seem to have an even higher 
potential for response to a second TNF blocker than primary 
non-responders. 
  The statement that there is no evidence for the efﬁ  cacy of 
other biological therapies in AS is also new. It is based on two 
studies evaluating rituximab and abatacept, which both failed to 
show convincing response rates in patients who had failed TNF 
blockers.    82        83    The response rate to rituximab in TNF-naive AS 
patients deserves further study.    82    
  Some experts stressed the importance of exercise and regular 
physiotherapy in patients with AS under treatment with TNF 
blockers, but the literature on this topic is still scarce.    84    
  Strength of recommendation: 9.4±0.2. 
    Surgery 
▶       Total hip arthroplasty should be considered in patients with 
refractory pain or disability and radiographic evidence of 
structural damage, independent of age. 
▶       Spinal corrective osteotomy may be considered in patients 
with severe disabling deformity. 
▶       In patients with AS and an acute vertebral fracture a spinal 
surgeon should be consulted. 
      For comparison, the old recommendation was: total hip arthro-
plasty should be considered in patients with refractory pain or 
disability and radiographic evidence of structural damage, inde-
pendent of age. Spinal surgery, such as corrective osteotomy and 
stabilisation procedures, may be of value in selected patients. 
  Comment 
  This bullet point was modiﬁ  ed based on discussions with the 
two orthopaedic surgeons in the expert committee. The sig-
niﬁ  cance of hip involvement has been conﬁ  rmed by a recent 
multinational study.    85        86    A statement related to that problem 
therefore remains important, and the ﬁ  rst sentence on total hip 
arthroplasty remains unchanged. Cement is only rarely used in 
young patients,    87    and heterotopic ossiﬁ  cation does not seem to 
be a problem in patients with AS.    88    The recommendation on 
spinal surgery was intensively discussed and a more detailed 
statement agreed on. 
  The second statement addresses an elective surgical proce-
dure in the spine, which was shown to be beneﬁ  cial for many 
patients with advanced AS and hyperkyphosis who have lost 
their horizontal vision ability. This technically challenging 
operation, which is only performed in experienced centres 
and is not available in some countries, leads to at least the 
partial correction of kyphosis. Triangular pieces of bone are 
removed from selected vertebral bodies (pedicle subtraction 
osteotomy) before the spine is re-stabilised by metallic bars 
and screws. 
  The third statement addresses spinal fractures that may lead 
to instability of the spine. These are often but not always rather 
acute clinical situations, which may or may not be associated 
with neurological symptoms.    89       –       94    In addition, as mechanical 
stress may prevent discovertebral spinal lesions from fusion 
and lead to the development of pseudarthrosis, a spinal surgeon 
should at least be consulted in patients with symptomatic dis-
covertebral lesions.    95    
  This has been regarded as so important that an extra bullet 
point, no 11, was added. 
  Strength of recommendation: 9.2±0.3. 
    Changes  in  the  disease  course 
▶       If a signiﬁ  cant change in the course of the disease occurs, 
causes other than inﬂ  ammation, such as a spinal fracture, 
should be considered and appropriate evaluation, including 
imaging, should be performed. 
    Comment 
  This is a new recommendation. The major point is that changes 
in the course of the disease should be carefully evaluated and 
MRI performed—especially in situations in which the nature of 
back pain changes. An experienced spinal surgeon may need to 
be consulted. It seems important to stress that not all AS patients 
with spinal fractures have neurological symptoms (and not all 
need to be operated on). 
  There are other important differential diagnoses such as spi-
nal infections. 
  Strength of recommendation: 9.0±0.3. 
     DISCUSSION 
  The ASAS/EULAR recommendations were successfully updated. 
The introduction of overarching principles led to some changes, 
eg, one bullet point and one sentence was moved to this sec-
tion. There are now 11 bullet points including two new points: 
one for extra-articular manifestations and one for changes in the 
clinical course of AS. 
  A patient version of the recommendations will be developed. 
We encourage translation of these recommendations into vari-
ous languages in a collaboration between rheumatologists and 
patients. After presentation at the EULAR 2010 meeting in Rome 
and publication in the EULAR journal, individual countries can 
now take on dissemination. 
  The collaboration between ASAS and EULAR has again been 
very successful and should be continued for the next update that 
may be renamed according to the new classiﬁ  cation critieria for 
axial spondyloarthritis. There will be a need for further discus-
sion as to whether the new criteria for peripheral spondyloar-
thritis    96    should give rise to separate recommendations for these 
patients. 
  Although it was decided that these recommendations con-
centrate on AS, the authors are well aware that the treatment 
of patients with non-radiographic axial spondyloarthritis is 
also a very important topic. There are now data of clinical 
trials available that address this question in a controlled man-
ner.    63        64    They provide evidence that anti-TNF agents work 
in early disease in at least the same but probably in an even 
superior way. 
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  The original publication has already set a standard for the 
management of patients with AS. As we feel that this update 
has even improved the original set we are conﬁ  dent that these 
recommendations will be useful for patients and healthcare 
workers, including rheumatologists and other physicians treat-
ing patients with AS, as well as physiotherapists. 
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